Matthias Kometer
Neuroscientist and Clinical Researcher
Data updated
Papers
Trials
Research Footprint
Matthias Kometer appears in 18 tracked papers (2010–2025), most studied alongside Psilocybin, Ayahuasca and Placebo, across Healthy Volunteers, Neuroimaging & Brain Measures and Schizophrenia.
Most-cited paper: The neurobiology of psychedelic drugs: implications for the treatment of mood disorders (706 citations).
Frequent co-authors: Franz Vollenweider, Milan Scheidegger and Erich Seifritz.
Background & Research
Matthias Kometer is a neuroscientist and clinical researcher known for a body of work that combines psychopharmacology, neuroimaging (fMRI/EEG) and cognitive neuroscience to study the effects of serotonergic psychedelics in humans. Working within clinical research groups that include the Vollenweider lab at the University of Zurich, Kometer has contributed key empirical studies and reviews that map the pharmacological, neural and psychological mechanisms of compounds such as psilocybin, DMT/ayahuasca-inspired formulations and classical hallucinogens. His research spans acute neural responses (including P300 and other event-related potentials), changes in default mode network connectivity, and behavioural outcomes such as empathy, moral decision-making and self–other processing.
Key Impact
Notable for pioneering human neuroimaging and psychopharmacological research that has elucidated how serotonergic psychedelics alter self-processing, affect and social cognition, and for translating these findings toward psychiatric applications.
Collaboration Network
22 collaborators· click a node to visit their profile
Full network →